Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 5, 2005, Pages 487-491

  Stathopoulos, G P ^a   Tsavdaridis, D ^b   Malamos, N A ^c   Rigatos, S K ^a   Kosmas, Ch ^d   Pergantas, N ^e   Stathopoulos, J G ^a   Xynotroulas, J ^a  

^a Errikos Dunant Hospital   (Greece)

^b IKA Hospital   (Greece)

^c HELENA VENIZELOU HOSPITAL   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

^e IKA   (Greece)

Author keywords

Breast cancer; Docetaxel; Irinotecan

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ONDANSETRON; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG INFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAMPLE SIZE; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CAMPTOTHECIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEUTROPENIA; TAXOIDS;

EID: 27644549882     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1006-3     Document Type: Article

References (38)

1. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter phase III trial. J Clin Oncol 21:968-975
2. A'Hern R, Smith I, Ebbs S (1993) Chemotherapy and survival in advanced breast cancer: the infusion of doxorubicin in Cooper type regimens. Br J Cancer 67:807-813
3. Weber BL, Vogel C, Jones S et al (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730
4. Gianni L, Munzone E, Capri G et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. J Clin Oncol 13:2688-2699
5. Dombernowsky P, Gehl J, Boesgaard M et al (1995) Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 22(Suppl 15):13-16
6. Seidman A, Reichman B, Crown J et al (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159
7. Kornek G, Ulrich-Pur H, Penz M et al (2001) Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 19:621-627
8. Greenberg PAC, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205
9. Falkson G, Tormey DC, Carey P et al (1991) Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer 27:973-977
10. Crown J (1999) A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol 26(Suppl):5-9
11. Trudeau ME, Eisenhauer EA, Higgins BP et al (1996) Docetaxel in patients with metastatic breast cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:422-428
12. Stathopoulos GP, Rigatos SK, Pergantas N et al (2002) Phase II Trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20:37-41
13. 2 as first-line chemotherapy for patients with advanced breast cancer. Br J Cancer 74:650-656
14. Chevallier B, Fumoleau P, Kerbrat P et al (1996) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the clinical screening co-operative group of the EORTC. Ann Oncol 7:165-171
15. Nabholtz JM, Senn HJ, Bezwoda WR et al (1999) Prospective randomized trial of docetaxel versus mitomycin C plus vin-blastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413-1424
16. Paridaens R, Biganzoli L, Bruming P et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organisation for Research and Treatment of Cancer Randomized Study with crossover. J Clin Oncol 18:724-733
17. Cunningham D, Pyrhonen S, James RD et al (1998) Randomized trial of irinotecan plus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418
18. Rougier P, van Cutsem E, Bajetta E et al (1998) Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
19. Sargent DJ, Niedzwiecki D, O'Connell MJ et al (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345:144-145
20. Douillard J, Cunningham D, Roth A et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041-1047
21. Sjöström J, Blomqrist C, Mouridsen H et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194-1201
22. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
23. Nabholtz JM, Mackey JR, Smylie M et al (2001) Phase II study of docetaxel, doxorubicin and cyclophosphamide as a first-line chemotherapy for metastatic breast cancer. J Clin Oncol 19:314-321
24. Misset JL, Dieras V, Gruia G et al (1999) Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10:553-560
25. Biganzoli L, Cufer T, Bruning P et al (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organisation for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114-3121
26. Jassem J, Pienowski T, Plzanka A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715
27. Rigatos SK, Stathopoulos GP, Pergantas N et al (2001) Docetaxel combined with irinotecan in pretreated advanced cancer patients phase I and II study, 11th international congress on anticancer treatment, vol 134, Paris (abstr S06)
28. Perez EA, Hillman DW, Mailliard JA et al (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline or taxane or both. J Clin Oncol 22:2849-2855
29. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588-592
30. Lucla HJ, Thomssen C, Untch M et al (2000) Multicenter phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC): a study of the AGO breast cancer group. Proc Am Soc Clin Oncol 19:73a (abstr 280)
31. Carmichael J (2001) UKCCR trial of epirubicin and cyclophosphamide (EC) vs epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20:22a. (abstr 84)
32. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
33. Albain KS, Nag S, Calderillo-Ruiz G et al (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as a front-line therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol 22(15 suppl):14S (abstr 510)
34. Fountzilas G, Kalofonos HP, Dafni V et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic cooperative oncology group. Ann Oncol 15:1517-1526
35. Perez EA, Hillman DW, Stella PJ et al (2000) A Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 88:124-131
36. Mitchell PLR, Basser R, Chipman M et al (2004) A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Ann Oncol 15:585-589
37. Tabernero J, Climent MA, Lluch A et al (2004) A multicentre randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365
38. Frasci G, Comello P, Thomas R et al (2004) Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol 53(1):25-32